JUL 22, 2020 12:29 PM PDT

Investigating a New Target Against Esophageal Cancer

WRITTEN BY: Jasper Cantrell

Esophageal cancer remains one of the most dangerous cancers in the world. Most therapies center around chemotherapy, radiotherapy, surgery, or a combination of these. Esophageal cancer has a low success rate with these treatments. However, research exposes new therapeutic targets every year.

One example that has developed from this is targeting the glycogen synthesis pathway. There is a clear decrease in glycogen levels in many cancers, so it stood to reason it would be a source of possible targeted therapies. A team from Kanazawa University in Japan studied it before and found that the protein GSK3β (glycogen synthase kinase 3β) might be a suitable target.

The team had previously identified that glycogen synthase (which makes glycogen from glucose), is inactivated by glycogen synthase kinase 3β. In esophageal cancer, GSK3β was more active than in healthy tissues and was associated with cancer progression. The team knew that GSK3β inhibition could suppress this pro-tumor activity but not how it did so. They began an investigation to figure out how GSK3β inhibition managed to suppress tumor growth.

They first confirmed that GSK3β levels were elevated in esophageal cancer versus healthy tissues. Inhibitors directed at GSK3β also impaired the growth of esophageal cancer cells, while healthy cells remained unaffected. These observations confirmed that GSK3β was an effective target for anti-cancer therapy.

The team knew that many cancer treatments work by impairing cancer growth by affecting the cell cycle, which usually resulted in the cell’s termination. They tested GSK3β inhibitors and found that they stalled cancer cells during the cell cycle. These cells were then confirmed to be terminated by apoptosis (a cell death pathway).

Finally, the team wanted to test the safety of GSK3β inhibitors in a mouse model. Application of GSK3β inhibitors to mice with tumors significantly slowed tumor growth, with the mice experiencing no adverse effects from the treatment.

This study provides substantial evidence supporting GSK3β inhibitors use as cancer therapeutics. The inhibitors managed to impair cell growth pathways by preventing the activation of GSK3β without harming healthy cells. One of the inhibitors tested is even in clinical trials, the final testing phase of new therapeutics.

The study concludes, “Taken together, the present study reinforces the notion that GSK3β is a potential therapeutic target in ESCC, thereby including this as another tumor type susceptible to GSK3β-targeted therapy.”

Sources: Nature Scientific Reports, Roswell Park Comprehensive Cancer Center

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
JUN 14, 2021
Health & Medicine
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
JUN 14, 2021
Another Benefit of Aspirin: Decreased Colorectal Cancer Risk When Started Early
Valued for stroke and heart attack prevention, aspirin is also recommended for colorectal cancer prevention. A Harv ...
JUN 11, 2021
Cell & Molecular Biology
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
JUN 11, 2021
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
The immune system can detect and destroy pathogenic and cancerous cells, but sometimes those dangerous cells can evade t ...
JUN 26, 2021
Cancer
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
JUN 26, 2021
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
Research shows that obese patients with cancers including ovarian and melanoma may respond better to a certain kind of i ...
SEP 06, 2021
Cancer
A New Biomarker to Personalize Breast Cancer Therapy
SEP 06, 2021
A New Biomarker to Personalize Breast Cancer Therapy
The American Cancer Society estimates that over 280,000 women in the United States will be diagnosed with breast cancer ...
SEP 02, 2021
Immunology
Hobit Activates Cancer-Killing Immune Cells
SEP 02, 2021
Hobit Activates Cancer-Killing Immune Cells
Innate lymphoid cells, or ILCs, are specialized immune cells that are increasingly entering the research spotlight. Thes ...
SEP 13, 2021
Cancer
Fat Loss can Predict Gastric Cancer Survival
SEP 13, 2021
Fat Loss can Predict Gastric Cancer Survival
Cancer cachexia is a metabolic disorder in cancer patients experiencing uncontrolled weight loss.  While cancer cac ...
Loading Comments...